Detection of Urothelial Tumors Differs by Location

Share this content:

(ChemotherapyAdvisor) – Detection levels of urothelial tumors changes based on location within the urinary tract, according to a team of Canadian researchers. This conclusion is based on a study entitled “Detection of Urothelial Tumors: Comparison of Urothelial Phase with Excretory Phase CT Urography—A Prospective Study,” which was published in Radiology on July 10.

In this study, the investigators aimed to “compare contrast material–enhanced computed tomographic (CT) urography 60 seconds after injection of contrast material (urothelial phase [UP]) after intravenous administration of a diuretic with the standard 5-minute delayed excretory phase (EP) in a high-risk population for upper tract tumors.”

The investigators administered a diuretic to eligible patients. This was followed by dual-phase CT urography at 60 seconds (UP) and 5 minutes (EP) after intravenous administration of contrast material. “Two experienced abdominal radiologists independently interpreted each phase more than 1 month apart to minimize recall bias. Urinary tract distention and location and size of all lesions suspected of being urothelial tumors were recorded,” the investigators wrote.

The investigators reported the following results. For detection of bladder tumors, there was higher sensitivity for the UP than the EP (89.3% [109 of 122] vs 70.5% [86 of 122], respectively; P<.0001). For detection of upper tract tumors, there was higher sensitivity for the UP than the EP (82.6% [38 of 46] vs 69.6% [32 of 46], respectively; P=.0194). Distention of all upper urinary tract segments was better during the EP than the UP (P<.0001).

The investigators concluded: UP CT urography exhibits a higher lesion detection rate than the EP for both upper and lower urinary tract tumors.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs